An Open-label, Single-arm Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents Aged ≥12 to ≤17 Years At the Time of Study Inclusion with Active Moderate to Severe Hidradenitis Suppurativa
Latest Information Update: 25 May 2025
At a glance
- Drugs Sonelokimab (Primary)
- Indications Hidradenitis suppurativa
- Focus Adverse reactions; Pharmacokinetics; Registrational
- Acronyms VELA-TEEN
- Sponsors MoonLake Immunotherapeutics
Most Recent Events
- 12 May 2025 Status changed from recruiting to active, no longer recruiting.
- 12 May 2025 According to a MoonLake Immunotherapeutics media release, top-line results for Phase 3 VELA program for the Nanobody sonelokimab in HS (around September 2025).
- 12 May 2025 According to a MoonLake Immunotherapeutics media release, the Company held an in-person and virtual Capital Markets Update in New York on Tuesday, April 29, 2025.